Taldefgrobep alfa received Fast Track designation for the treatment of spinal muscular atrophy. Credit: Jensflorian / Wikimedia.

The US Food and Drug Administration (FDA) has granted Fast Track designation for Biohaven’s new anti-myostatin adnectin, taldefgrobep alfa, to treat spinal muscular atrophy (SMA).

The new myostatin-targeting biologic investigational agent has been designed for specific binding to myostatin (GDF-8) to reduce overall levels of myostatin.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It also works as a receptor antagonist to block myostatin signalling in skeletal muscles.

Taldefgrobep is a complete human anti-myostatin recombinant protein that is developed for lowering free myostatin.   

Biohaven stated that taldefgrobep can also be used along with disease-modifying therapies for improving muscle function by blocking the activity of myostatin.

Previously, the US FDA granted orphan drug designation to taldefgrobep to treat SMA, a rare and progressively debilitating motor neuron disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biohaven Clinical Development vice-president Lindsey Lee Lair said: “We are very pleased the FDA granted Fast Track designation for taldefgrobep alfa for the treatment of SMA.

“Children and adults living with SMA experience significant muscle weakness and functional impairments affecting their quality of life daily, and a substantial unmet medical need persists.

“We are excited about the potential for taldefgrobep alfa to improve the lives of patients and families affected by SMA.”

Currently, the company is enrolling participants in a Phase III clinical trial of taldefgrobep to treat SMA.

The randomised, double-blind, placebo-controlled trial has been designed for assessing the safety and efficacy of taldefgrobep alfa as an adjunctive therapy for people already taking a stable nusinersen or risdiplam dose or with an onasemnogene abeparvovec-xioi history, against placebo.

According to Biohaven, SMA affects nearly one in 11,000 births in the US, and it is a genetic carrier in approximately one in every 50 Americans.